In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...
A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...
ABC 11 Raleigh, NC on MSN
Duke Eye Center pioneers new gene therapy for rare eye disease, MacTel
Duke Eye Center has become the first academic medical center in the country to implant a new cell-based gene therapy for a rare eye disease called MacTel. This procedure offers hope to patients like ...
In honor of World Blindness Awareness Month, "GMA" is spotlighting a breakthrough gene therapy that's helping some blind ...
Long-term follow-up shows 95% success rate, no serious complications in largest ADA-SCID gene therapy study to date ...
In the spring of 2024, the US Food and Drug Administration (FDA) approved fidanacogene elaparvovec (Beqvez), only the second gene therapy product for hemophilia B. Just a few months later, the Pfizer ...
The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.
The trial was small — just 12 children were treated in one or both ears — but it offers important lessons for researchers ...
With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.
Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback